Evidence map›Paper›PMID 24664896›Full record

ReviewWiley interdisciplinary reviews. RNA

The multifaceted roles of RNA binding in APOBEC cytidine deaminase functions.

Kimberly M Prohaska, Ryan P Bennett, Jason D Salter, Harold C Smith

Abstract readReview
In one paragraph

Review in Wiley interdisciplinary reviews. RNA. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Lactobacillus for ribosome peptide editing cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Post-transcriptional regulation of LINE-1 retrotransposition by AID/APOBEC and ADAR deaminases.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2018
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kimberly M ProhaskaOyaGen Inc, Rochester BioVenture Center, Rochester, NY, USA.
Ryan P Bennett
Jason D Salter
Harold C Smith
OyaGen (United States) · US

Funding

Discovery of Chemical Probes for RNA-Binding Protein Host Defense FactorsR01GM110119 · NIGMS · OYAGEN, INC. · PI SMITH, HAROLD C · 2015 to 2017
$1.8M
METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITINGR01DK043739 · NIDDK · UNIVERSITY OF ROCHESTER · PI SMITH, HAROLD C · 1992 to 2003
$1.1M
Investigation of APOBEC3G/Vif Interactions by SAXS and X-ray CrystallographyR33AI076085 · NIAID · UNIVERSITY OF ROCHESTER · PI WEDEKIND, JOSEPH E · 2010 to 2012
$1.1M
The Role of mRNA Editing in B Cell DevelopmentR21AI054369 · NIAID · UNIVERSITY OF ROCHESTER · PI SMITH, HAROLD C · 2003 to 2004
$473k
Based deamination by CEM15 suppresses HIV-1 InfectivityR21AI058789 · NIAID · UNIVERSITY OF ROCHESTER · PI SMITH, HAROLD C · 2004 to 2005
$468k
Development of a Novel HIV/AIDS Therapeutic Activating the APOBEC3G Host DefenseR21AI095007 · NIAID · OYAGEN, INC. · PI SMITH, HAROLD C · 2011 to 2012
$462k
Investigation of APOBEC3G/Vif Interactions by SAXS and X-ray CrystallographyR21AI076085 · NIAID · UNIVERSITY OF ROCHESTER · PI WEDEKIND, JOSEPH E · 2008 to 2009
$424k
Development of a High Throughput Screen for Antagonists of Vif DimerizationR21NS067671 · NINDS · OYAGEN, INC. · PI SMITH, HAROLD C · 2009 to 2011
$161k
NIAID NIH HHS AI076085NIAID NIH HHS AI095007NIAID NIH HHS AI54369NIAID NIH HHS AI58789NIAID NIH HHS R21 AI054369NIAID NIH HHS R21 AI058789NIAID NIH HHS R21 AI076085NIAID NIH HHS R21 AI095007NIAID NIH HHS R33 AI076085NIDDK NIH HHS DK43739NIDDK NIH HHS R01 DK043739NIGMS NIH HHS R01 GM110119NINDS NIH HHS NS067671NINDS NIH HHS R21 NS067671
6 · The paper itself

Abstract

Cytidine deaminases have important roles in the regulation of nucleoside/deoxynucleoside pools for DNA and RNA synthesis. The APOBEC family of cytidine deaminases (named after the first member of the family that was described, Apolipoprotein B mRNA Editing Catalytic Subunit 1, also known as APOBEC1 or A1) is a fascinating group of mutagenic proteins that use RNA and single-stranded DNA (ssDNA) as substrates for their cytidine or deoxycytidine deaminase activities. APOBEC proteins and base-modification nucleic acid editing have been the subject of numerous publications, reviews, and speculation. These proteins play diverse roles in host cell defense, protecting cells from invading genetic material, enabling the acquired immune response to antigens and changing protein expression at the level of the genetic code in mRNA or DNA. The amazing power these proteins have for interphase cell functions relies on structural and biochemical properties that are beginning to be understood. At the same time, the substrate selectivity of each member in the family and their regulation remains to be elucidated. This review of the APOBEC family will focus on an open question in regulation, namely what role the interactions of these proteins with RNA have in editing substrate recognition or allosteric regulation of DNA mutagenic and host-defense activities.

Indexed as

APOBEC-1 DeaminaseBinding SitesCytidine DeaminaseRNAAPOBEC-1 DeaminaseCytidine DeaminaseRNA

Identifiers

PMID24664896
PMCPMC4062598
OpenAlexW2110297052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.